New biologics outsourcing solution provider leverages proven track record of Tanvex BioPharma USA Inc. to help early-stage companies bring mammalian and microbial derived biologics from concept to commercialization. SAN DIEGO, October 16, 2023 (Newswire.com) – Tanvex BioPharma USA Inc., a developer and manufacturer of biopharmaceuticals, has launched Tanvex CDMO to provide comprehensive biologic contract development […]

Tanvex BioPharma, Inc., Chairman Yen Yun emphasized that the company is actively building a comprehensive CDMO service platform. Combined Tanvex Taiwan’s long-established upstream process development capability with the experience of Tanvex USA in passing the US Food and Drug Administration’s (FDA) strict facility inspections and their good manufacturing practices (GMP) for local production, Tanvex aims […]

Tanvex BioPharma, Inc., has announced that its subsidiary, Tanvex BioPharma USA, Inc. has entered into a distribution agreement with Sandoz AG for Nypozi (filgrastim) in Canada. Under the terms of the deal, Tanvex will receive an upfront payment, payments for supply and contingent payments based on sales and profit from the product. All other terms […]

Tanvex announced that the company has reached an agreement with Genentech to settle the patent litigation related to certain patents associated with Herceptin®. The legal action, which is pending in the U.S. District Court for the Southern District of California, will be dismissed as a result of the settlement. In addition to the United States, […]